Kaposi's sarcoma medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 20: | Line 20: | ||
* Management strategies varies depending on the specific variant of Kaposi's sarcoma such as: | * Management strategies varies depending on the specific variant of Kaposi's sarcoma such as: | ||
:* Classic Kaposi's sarcoma managemenet may range from no treatment to either [[radiotherapy]], local therapeutic interventions, or [[surgery|surgical excision]]. | :* Classic Kaposi's sarcoma managemenet may range from no treatment to either [[radiotherapy]], local therapeutic interventions, or [[surgery|surgical excision]]. | ||
:* Iatrogenic Kaposi's sarcoma management focuses on modifying [[immunosuppressive therapy]] in addition to local therapeutic interventions. | :* Iatrogenic Kaposi's sarcoma management focuses on modifying the patients [[immunosuppressive therapy]] in addition to local therapeutic interventions. | ||
:* Endemic Kaposi's sarcoma is primarily manage by systemic [[chemotherapy]] | :* Endemic Kaposi's sarcoma is primarily manage by systemic [[chemotherapy]] | ||
:* There is no curative treatment for epidemic Kaposi's sarcoma; the mainstay management for such patients is [[Highly active antiretroviral therapy|HAART therapy]] which aims for the control of Kaposi's sarcoma progression. | :* There is no curative treatment for epidemic Kaposi's sarcoma; the mainstay management for such patients is [[Highly active antiretroviral therapy|HAART therapy]] which aims for the control of Kaposi's sarcoma progression. | ||
| Line 51: | Line 51: | ||
:* Tyrosine kinase inhibitors ([[imatinib]]) | :* Tyrosine kinase inhibitors ([[imatinib]]) | ||
:* Matrix metalloproteinases | :* Matrix metalloproteinases | ||
==References== | ==References== | ||
Revision as of 21:59, 21 January 2016
|
Kaposi's sarcoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Kaposi's sarcoma medical therapy On the Web |
|
American Roentgen Ray Society Images of Kaposi's sarcoma medical therapy |
|
Risk calculators and risk factors for Kaposi's sarcoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2]
Overview
The optimal therapy for Kaposi's sarcoma depends on multiple factors. Management strategies varies depending on the specific variant of Kaposi's sarcoma. Classic Kaposi's sarcoma management may range from no treatment to either radiotherapy, local therapeutic interventions, or surgical excision. Iatrogenic Kaposi's sarcoma management focuses on modifying immunosuppressive therapy in addition to local therapeutic interventions. Endemic Kaposi's sarcoma is primarily manage by systemic chemotherapy. However, there is no curative treatment for epidemic Kaposi's sarcoma; the mainstay management for such patients is HAART therapy which aims for the control of Kaposi's sarcoma progression.[1][2]
Medical Therapy
- The anatomical location of the tumor
- The specific variant of Kaposi's sarcoma
- The rate of distribution and progression of Kaposi's sarcoma lesions
- The patients clinical presentation
- The efficacy and potential side effects of therapy
- The presence or absence of HIV infection
- The degree of immune suppression
- The presence of other comorbidities
- The preference and prognosis of the patients
- Management strategies varies depending on the specific variant of Kaposi's sarcoma such as:
- Classic Kaposi's sarcoma managemenet may range from no treatment to either radiotherapy, local therapeutic interventions, or surgical excision.
- Iatrogenic Kaposi's sarcoma management focuses on modifying the patients immunosuppressive therapy in addition to local therapeutic interventions.
- Endemic Kaposi's sarcoma is primarily manage by systemic chemotherapy
- There is no curative treatment for epidemic Kaposi's sarcoma; the mainstay management for such patients is HAART therapy which aims for the control of Kaposi's sarcoma progression.
- Local/regional therapy recommended for the management of Kaposi's sarcoma patients may include:
- Intralesional vinca-alkaloids, bleomycin, and interferon-alpha
- Topical 0.1% alitretinoin
- Imiquimod cream
- Radiotherapy
- Laser therapy
- HAART therapy regimens recommended for the management of Kaposi's sarcoma patients may include:
- Non nucleoside reverse transcriptase (NNRT)-based therapy
- Protease Inhibitor (PI)-based therapy
- Chemotherapy regimens recommended for the management of Kaposi's sarcoma patients may include:
- Liposomal anthracyclins
- Paclitaxel
- Oral etoposide
- Doxorubicin AND bleomycin AND vincristine
- Doxorubicin AND bleomycin AND vinblastine
- Immune modulators recommended for the management of Kaposi's sarcoma patients may include:
- Targeted therapies recommended for the management of Kaposi's sarcoma patients may include:
- Antiherpes therapy
- Angiogenic inhibitors (thalidomide)
- VEGF inhibitors (bevacizumab)
- Tyrosine kinase inhibitors (imatinib)
- Matrix metalloproteinases
References
- ↑ 1.0 1.1 Fatahzadeh M (2012). "Kaposi sarcoma: review and medical management update". Oral Surg Oral Med Oral Pathol Oral Radiol. 113 (1): 2–16. doi:10.1016/j.tripleo.2011.05.011. PMID 22677687.
- ↑ 2.0 2.1 Masur H, Brooks JT, Benson CA, Holmes KK, Pau AK, Kaplan JE; et al. (2014). "Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Updated Guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America". Clin Infect Dis. 58 (9): 1308–11. doi:10.1093/cid/ciu094. PMC 3982842. PMID 24585567.